- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02337647
Evaluation of the Distortion Correction Data Collection (DCDC) App Software
Evaluation of the Distortion Correction Data Collection (DCDC) App Software to Repair Visual Distortions for Low Vision Age-related Macular Degeneration, and the Correlation of the Distortions With Clinical Examination
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This research study is a phase 1 clinical trial to evaluate the efficacy of the Distortion Correction Data Collection (DCDC) App on a computer tablet system. There are two objectives in this study. The primary objective is to evaluate the functionality of the visual distortion app on the tablet computer. Patients will draw their distortions on the tablet screen, and the app will record and correct the distortions.The second objective is to create a distortion data repository (DDR) that contains retinal maps, data pertaining to the anatomical and functional aspects of patients retinas and the distortions. This DDR will be used to correlate retinal health to distortions.The correlation will be key in improving the correction software of the app. Long term, the app will be used to create a diagnostic tool and improve image processing in retinal prosthesis systems.
Participating subjects must be at least 55 years of age or older with age-related macular degeneration (AMD). After consent, a chart review will be performed. At the baseline visit, subjects will have an electroretinogram (ERG). At the single study visit, to be scheduled within 2 weeks of the baseline visit, subjects will use the DCDC app on a tablet computer to trace their visual distortions on an Amsler grid. Up to 5 subjects who meet the inclusion/exclusion criteria will be enrolled. The duration of the study is a 2 hour baseline visit and a 1 hour study visit, all within 2 weeks.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Nebraska
-
Omaha, Nebraska, United States, 68198-5540
- University of Nebraska Medical Center, Truhlsen Eye Institute
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- 55 years of age or greater
- Diagnosed with age-related macular degeneration (AMD).
- Best corrected visual acuity (BCVA) of (20/40 to 20/200 Snellen equivalent).
- Visual distortion is present in at least one eye, as determined by Amsler grid evaluation.
- Have had the following imaging tests completed within the past three months as part of standard of care: optical coherence tomography (OCT), scanning laser ophthalmoscopy (SLO), and Fluorescein angiography (FA).
- Capable of understanding the requirements of the study, willing to follow study instructions, able to provide written informed consent to participate, and willing to comply with all study requirements.
- Women who are post-menopausal or not otherwise of child-bearing potential -
Exclusion Criteria:
- Visual field loss from diseases other than AMD.
- Visual distortions from the following conditions other than AMD: epiretinal membrane, diabetic macular edema, central retinal vein occlusion (CRVO) with edema, and cystoid macular edema.
- A medical condition, serious concurrent illness, or extenuating circumstance that would significantly decrease ability to follow study instructions.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: DCDC app
Subjects will evaluate the DCDC app
|
The DCDC app is an experimental software that allows users to map their visual distortions on a tablet computer.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Functionality of the Distortion Correction Data Collection App (DCDC), as measured by successful usage of the app by subjects.
Time Frame: 3 months
|
Subjects will use the app to trace visual distortions.
The app will correct these distortions, subjects will give feedback on these corrections.
Test will be repeated two times.
|
3 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Vikas Gulati, MD, University of Nebraska
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 0625-14-FB
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Age-related Macular Degeneration
-
Novartis PharmaceuticalsCompletedNeovascular Age-Related Macular DegenerationChina
-
Hoffmann-La RocheWithdrawnNeovascular Age-Related Macular DegenerationDenmark, Argentina, Hong Kong, Thailand, Portugal, Greece, Spain
-
Novartis PharmaceuticalsCompletedNeovascular Age-Related Macular DegenerationSpain, Italy, Germany, Canada, Ireland
-
Novartis PharmaceuticalsTerminatedNeovascular Age-Related Macular Degeneration
-
Regeneron PharmaceuticalsCompletedNeovascular Age Related Macular DegenerationUnited States
-
Hoffmann-La RocheRecruitingNeovascular Age Related Macular Degeneration | nAMDChina
-
Ocular Therapeutix, Inc.Duke University; FortreaRecruitingNeovascular Age-Related Macular DegenerationUnited States
-
Innostellar Biotherapeutics Co.,LtdRecruitingNeovascular Age-Related Macular DegenerationChina
-
Ocular Therapeutix, Inc.CompletedNeovascular Age-Related Macular DegenerationUnited States
-
Novartis PharmaceuticalsWithdrawn
Clinical Trials on DCDC App
-
University of VictoriaRecruiting
-
Hypnalgesics, LLCTufts UniversityCompletedDental Anxiety | Opioid Use | Drug Use | Dental PainUnited States
-
Barbara Ann Karmanos Cancer InstituteCompletedCancer | Financial Toxicity | Question Prompt ListUnited States
-
Big Health Inc.National Institute of Mental Health (NIMH); Duke UniversityActive, not recruiting
-
University Hospitals Cleveland Medical CenterNot yet recruiting
-
Chang Gung UniversityChang Gung Memorial HospitalRecruiting
-
University of California, San FranciscoConquer Cancer FoundationCompletedProstate Cancer | Metastatic Prostate Cancer | Metastatic Castration-resistant Prostate CancerUnited States
-
The University of Hong KongNot yet recruitingDigital Health | Knee Pain/OsteoarthritisHong Kong
-
University of Sao PauloNot yet recruitingPostpartum Depression
-
Florida Atlantic UniversityCompletedHealth BehaviorUnited States